Insulet (PODD): Growth Runway Still Justifies a Buy

Thesis

Insulet Corporation (PODD) is one of the cleaner growth stories in medical devices: a category leader with a differentiated product, recurring revenue, expanding margins, and a long runway in both type 1 and type 2 diabetes. The core bull case rests on hard numbers. Revenue reached $2.71B in 2025, up 30.7% YoY, gross margin expanded to 71.6% from 69.8% in 2024, operating margin rose to 17.5% from 14.9%, and free cash flow climbed to $377.7M from $305.4M. That combination matters. Plenty of device companies can grow fast, and plenty can print margins. Fewer can do both at once while still funding global expansion and next-generation R&D.

The second leg of the thesis is market structure. Management said Insulet closed 2025 with its 10th consecutive year of 20% or greater constant-currency revenue growth, and the company still sees a $30B+ total addressable market across U.S. type 1, U.S. type 2, and international markets. In the U.S. type 1 market alone, management sized the opportunity at more than $9B with AID penetration at 40%. In U.S. type 2, management cited a market above $12B with AID penetration below 5%. Internationally, management said the type 1 market alone exceeds $10B, while only 1 in 4 people with diabetes outside the U.S. uses AID therapy. Those are not mature-market saturation numbers. They are early-to-middle innings numbers.

The main reason to stay balanced rather than euphoric is valuation discipline and execution risk. Even after the stock reset, PODD still carries a trailing P/E of 48.1 and a forward P/E of 27.2. The business also remains heavily concentrated in the Omnipod platform, and the 10-K makes clear that manufacturing scale, reimbursement, regulatory compliance, cybersecurity, and supplier concentration remain real operating risks. For a moderate-risk investor with a medium-term horizon, the setup is attractive because the business quality is high and the growth runway is visible. The catch is simple: this is a premium business, so the entry price still matters.

Company Overview

Insulet (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts, was incorporated in 2000, went public in 2007, and employs 5,400 people. It operates in Healthcare, specifically Medical Devices, and its business is built around the Omnipod platform.

The Omnipod platform includes Omnipod 5, Omnipod DASH, and the legacy Classic Omnipod system, though the 10-K states that the vast majority of the customer base is no longer using Classic Omnipod and that product is being phased out. Omnipod 5 is the flagship. It is a tubeless automated insulin delivery system with an algorithm embedded in the pod, integration with third-party CGMs, and smartphone or controller-based operation. Insulet also has a smaller drug-delivery business that produces pods for Amgen’s Neulasta Onpro kit.

Financially, this is now a much larger and more profitable company than it was a few years ago. Revenue rose from $1.10B in 2021 to $2.71B in 2025. Net income moved from $16.8M in 2021 to $247.1M in 2025, despite some year-to-year volatility from taxes and financing effects. Gross profit reached $1.94B in 2025, and EBITDA was $564.2M. Market cap stands at about $11.6B. This is no longer a niche concept stock. It is a scaled diabetes technology platform with meaningful earnings power.

Business Segment Deep Dive

Insulet’s economic engine is overwhelmingly Omnipod. Segment data shows 2025 revenue of $2.708B, with $34.1M from Drug Delivery, or 1.3% of total revenue. That leaves the rest tied to Omnipod-related sales. In plain English, this is a focused company, not a diversified conglomerate. Focus can be a strength when the product wins. It can also magnify risk if the product stumbles.

Geographically, the business breaks down more clearly. In Q4 2025, U.S. Omnipod revenue was $567.8M, up 28.0% YoY, while international Omnipod revenue was $214.0M, up 50.7% reported and 41.7% constant currency. For full-year 2025, U.S. Omnipod revenue reached $1.9B, up 27.2%, and international Omnipod revenue reached $754.3M, up 44.1% reported and 39.3% constant currency. The U.S. remains the profit anchor, but international is the faster-growing leg.

That mix matters because it says two useful things at once. First, Insulet still has deep room to grow in its home market, especially in type 2 diabetes. Second, the international business is not a side project. It is already a substantial revenue stream approaching three-quarters of a billion dollars and growing materially faster than the core U.S. base. When a company can compound off both penetration and geography, the runway gets longer than the headline multiple first suggests.

The smaller Drug Delivery business is useful but not thesis-defining. At 1.3% of 2025 revenue, it is too small to drive valuation on its own. It does, however, provide a modest diversification benefit and shows that Insulet’s pod manufacturing capabilities have applications beyond diabetes. Still, investors buying PODD are buying Omnipod. The rest is garnish, not the meal.

Flagship Product Analysis

Omnipod 5 is the centerpiece of the story. The 10-K describes it as an automated insulin delivery system with a proprietary algorithm embedded in the pod, integration with Dexcom G6, Dexcom G7, and Abbott FreeStyle Libre 2 Plus in various markets, and full smartphone compatibility in the U.S. It is tubeless, disposable, waterproof up to 25 feet for 60 minutes, and worn for up to three days. Those product details are not cosmetic. In diabetes care, convenience is adherence, and adherence is economics.

Commercial traction supports that product case. Management said Insulet had more than 600,000 estimated active Omnipod users globally as of Q4 2025. In the U.S., over 95% of the customer base was on Omnipod 5, and internationally over 60% of the customer base was on Omnipod 5. In Q4 2025, over 85% of U.S. new customer starts came from multiple daily injections, and type 2 represented over 40% of all starts. That is a strong sign that Omnipod 5 is not just winning switchers from rival pumps. It is expanding the category by pulling patients off injections.

The affordability and access angle also stands out. Management said Omnipod is available in about 48,000 U.S. pharmacies and covered for more than 90% of insured lives, or about 300 million of 317 million insured people. Management also said most users pay about $1 a day through the pay-as-you-go model and preferred formulary position. That pharmacy-channel model is a meaningful differentiator because it lowers friction at the point of adoption. In device markets, the best product does not always win. The product that is easiest to prescribe, easiest to reimburse, and easiest to start often does.

Omnipod 5 also benefits from a recurring revenue structure. Pods are disposable and replaced every few days, which creates durable follow-on demand once a patient is onboarded and retained. That is why management repeatedly emphasized retention, customer lifetime value, and the recurring nature of the model. The business behaves less like a one-time hardware sale and more like a razor-and-blades system, except the blades are medically necessary and sticky.

Innovation & Competitive Advantage

Insulet’s moat starts with product design. The company describes itself as the global leader in tubeless insulin pump technology, and the tubeless form factor remains the clearest point of separation from traditional tubed pumps. The 10-K also shows substantial IP depth, with more than 1,000 patents issued in the U.S. and other countries as of December 31, 2025, plus more than 700 patent applications pending. Patent counts alone do not guarantee dominance, but they do matter in a device category where hardware design, software, algorithms, and user interface all interact.

The moat is also widening through interoperability. In 2025, Insulet launched Omnipod 5 with Dexcom G7 in the U.S. iOS app and in Germany, Sweden, Denmark, Finland, and Italy. The company also launched Omnipod 5 integration with Abbott’s FreeStyle Libre 2 Plus in Australia. Management said it plans to add FreeStyle Libre 3 Plus and make Omnipod 5 compatible with every major sensor. In a market where CGM choice influences pump choice, broader compatibility is a serious commercial weapon.

Clinical and commercial evidence reinforce the moat. Management said Omnipod 5 was the favorite pump among both type 1 and type 2 users in the U.S. in 2025, that Omnipod is the most requested, most preferred, and most prescribed AID system, and that 70% of new customers who walk into a prescriber’s office with a brand request ask for Omnipod 5. Management also said the expanded sales force is more than 25% larger than the nearest competitor. That combination of product preference, prescriber demand, and sales reach is hard to dismiss.

The next layer of advantage is the pipeline. In December 2025, Insulet received FDA 510(k) clearance for Omnipod 5 algorithm enhancements that include a 100 mg/dL target glucose option and improved time in automated mode. Management also said Omnipod 6 is targeted for launch in 2027, with a smarter algorithm, expanded on-body placement flexibility, real-time software updates, and a single updatable pod platform compatible across CGM systems. For type 2 diabetes, management expects to initiate the pivotal EVOLUTION study in 2026, support a regulatory filing in 2027, and target commercial launch in 2028 for a fully closed-loop system. That is a healthy cadence of innovation, not a company coasting on one hit.

Operations & Supply Chain

Insulet manufactures at highly automated facilities in Acton, Massachusetts and Johor, Malaysia, and also uses manufacturing lines at a contract manufacturer facility in China. The company is investing in a third manufacturing plant in Costa Rica expected to be operational in 2029. That footprint matters because Omnipod is a high-volume disposable device business. Manufacturing efficiency is not a back-office detail here. It is a core driver of gross margin and service reliability.

The recent operating numbers show real progress. Q4 2025 gross margin was 72.5%, up 40 bps YoY, and full-year 2025 gross margin was 71.6%, up 180 bps. Management attributed the improvement to robust top-line growth, manufacturing productivity gains at Acton and Malaysia, positive pricing, and increased volumes. Malaysia became margin accretive just one year after coming online. That is a strong execution marker. New capacity often arrives with a temporary margin headache. Here, it turned accretive quickly.

Capital spending reflects the scale-up. CapEx rose to $191.6M in 2025 from $124.9M in 2024, and Q4 CapEx alone was $135.1M as Insulet expanded Malaysia and began development of Costa Rica. Free cash flow still increased to $377.7M in 2025 from $305.4M in 2024, which means the company funded heavier investment while still improving cash generation. That is usually what investors want from a growth manufacturer: spend more, but spend from strength.

The risk side is straightforward. The 10-K says some components are sole-sourced or sourced from a limited number of suppliers due to proprietary know-how, quality, cost, or regulatory constraints. Insulet specifically relies on a limited number of suppliers for application-specific integrated circuit chips, Bluetooth low-energy chips, and other specialized parts. The company mitigates risk by holding inventory in-house and at suppliers, but supplier concentration remains a live issue. In a disposable medical device model, a missing chip can turn a growth story into a logistics story very quickly.

Market Analysis

Insulet operates in one of the more attractive pockets of medtech: diabetes technology tied to recurring consumables, connected care, and rising adoption of automated insulin delivery. Management sized its own total addressable market at more than $30B across U.S. type 1, U.S. type 2, and international markets. That internal figure is broader than the traditional insulin pump market because it includes category expansion from multiple daily injections into AID.

Management’s market detail is especially useful. In U.S. type 1, the company cited a market above $9B with AID penetration at 40% versus CGM penetration at 70%. In U.S. type 2, management cited a market above $12B with AID penetration below 5% versus CGM adoption around 55%. Internationally, management said the type 1 market alone exceeds $10B, while only 1 in 4 people with diabetes outside the U.S. uses AID therapy even as CGM penetration reaches around 65%. Those gaps between CGM adoption and AID adoption are the opening. They imply that many patients and prescribers already accept glucose sensing but have not yet moved to automated insulin delivery.

External market data supports the broader category tailwind. Grand View Research estimates the global insulin pump market at $6.45B in 2025 and $9.66B by 2030, an 8.42% CAGR. That external figure is narrower than Insulet’s TAM framing, but it still points to a healthy growth market. The difference between the two figures is important. The external pump market measures the category as it exists today. Insulet’s TAM measures the category as it could look if AID penetrates more deeply into type 2 diabetes and more geographies.

Insulet’s 2025 performance suggests it is taking share while the market itself expands. Full-year revenue grew 30.7%, far faster than the broader insulin pump market growth rate implied by external forecasts. That usually means some mix of share gains, category expansion, and geographic rollout. In this case, the evidence points to all three.

Customer Profile

Insulet serves insulin-dependent diabetes patients, primarily people with type 1 diabetes and insulin-requiring type 2 diabetes. The 10-K estimates approximately 6 million people with type 1 diabetes in countries the company currently serves, approximately 6 million people with insulin-requiring type 2 diabetes in those countries, and another 3 million people with type 2 diabetes in the U.S. who require only basal insulin. That is a large clinical population before even accounting for future geographic expansion.

The customer profile is broadening in a way that matters for growth durability. Management said the U.S. prescriber base now includes more than 30,000 healthcare professionals, up about 28% YoY, and the type 2 prescriber base grew 62% in 2025 to more than 6,500 clinicians. That shift beyond endocrinology into primary care is a major strategic point. Type 1 diabetes is a strong market, but it is a narrower specialist-driven market. Type 2 is where the volume lives.

Commercial behavior also looks healthy. In Q4 2025, over 85% of U.S. new customer starts came from MDI, and type 2 represented over 40% of all starts. That means Insulet is not relying solely on pump-to-pump conversions. It is converting injection users, which is the larger pool. Management also said record new customer starts were achieved in both the U.S. and international markets in Q4 and for full-year 2025. When a device company starts pulling from the untreated or underpenetrated population rather than just swapping users with rivals, the runway gets much longer.

The payer and channel profile also supports adoption. In the U.S., Insulet sells primarily through wholesalers into the pharmacy channel and has reimbursement contracts in all 50 states. The company said Omnipod is covered for more than 90% of insured lives and available in roughly 48,000 pharmacies. That is a practical advantage for both patients and prescribers. In healthcare, friction is often the real competitor.

Competitive Landscape

The direct competitive set includes Tandem Diabetes Care, Medtronic Diabetes, and smaller emerging AID players such as Beta Bionics. Tandem’s t:slim X2 and Mobi compete most directly in the U.S. AID market, while Medtronic’s MiniMed 780G remains a major legacy competitor with scale and installed base. Dexcom and Abbott are not pump competitors, but they are strategically important because CGM integration affects pump competitiveness.

Insulet’s clearest edge is the tubeless patch-pump form factor. Traditional tubed pumps still work, but they carry more visible device burden. Omnipod’s disposable tubeless design, smartphone control, and broad pharmacy access create a simpler user proposition. That simplicity is not just a marketing line. Management said both type 1 and type 2 users in the U.S. named Omnipod 5 their favorite pump in 2025, and the company maintained the #1 most requested and #1 most prescribed AID system in the U.S. in 2025.

Relative to Tandem, Insulet appears to have stronger momentum in new customer starts and a more distinctive form factor. Relative to Medtronic, Insulet looks more agile in tubeless AID and is growing faster, while Medtronic retains scale and broader diabetes infrastructure. The competitive risk is not that Omnipod suddenly becomes a bad product. The risk is that rivals narrow the convenience gap, improve interoperability, or win payer positioning. In medtech, moats rarely disappear overnight. They erode one feature, one contract, and one prescriber relationship at a time.

Insulet’s answer to that risk is visible in the data: more than 1,000 patents, more than 700 pending applications, a sales force more than 25% larger than the nearest competitor, compatibility expansion across major CGMs, and a pipeline that includes Omnipod 6 and a fully closed-loop type 2 system. That is the right playbook. In a fast-moving device category, standing still is just a slower form of losing.

Macro & Geopolitical Landscape

The macro backdrop for Insulet is better than it is for many medical device companies because diabetes care is tied to chronic disease management rather than discretionary procedures. Demand is supported by aging populations and rising chronic disease prevalence. The World Health Organization has said the share of the global population over 60 is expected to rise from 12% in 2015 to 22% by 2050, and diabetes is one of the common chronic conditions associated with older populations. That is a long-duration demand tailwind.

The broader medical device market is also expanding. Mordor Intelligence estimates the global medical device technologies market at about $681.6B in 2025, rising toward roughly $955.5B by 2030. Connected care, monitoring devices, and home-health settings are among the faster-growing areas. Insulet fits that trend well because Omnipod sits at the intersection of wearable devices, software, remote data, and recurring home use.

The geopolitical and regulatory side is more mixed. Insulet manufactures in the U.S. and Malaysia, uses a contract manufacturer in China, and is building a plant in Costa Rica. That diversified footprint helps, but it also exposes the company to cross-border logistics, trade friction, and regulatory complexity. The 10-K also highlights compliance obligations tied to FDA regulation, HIPAA, GDPR, anti-kickback statutes, and cybersecurity. FDA guidance issued in February 2026 on cybersecurity in medical devices reinforces that connected-device makers now need security discipline as part of product design, not as an afterthought.

Currency is another variable, though it has recently been favorable. Management said foreign exchange was expected to add about 100 bps to full-year 2026 revenue growth and about 300 bps to international growth. Helpful, yes. Thesis-defining, no. The bigger macro point is that Insulet is exposed to global healthcare systems and reimbursement frameworks, but it sells into a category with durable clinical need and relatively low economic sensitivity.

Balance Sheet Health

Income Statement Strength

Estimates Outlook

Valuation Assessment

Target Prices & Recommendation

Closing

Insulet (PODD) has built one of the stronger business models in medtech. The company combines a differentiated device, recurring consumables revenue, expanding global reach, rising profitability, and a still-underpenetrated market. 2025 results were strong across the board: $2.71B in revenue, 30.7% growth, 71.6% gross margin, 17.5% operating margin, and $377.7M in free cash flow. Management then followed that with 2026 guidance calling for another 20% to 22% revenue growth and more than 25% adjusted EPS growth.

That does not make the stock risk-free. Omnipod concentration, supplier dependencies, reimbursement complexity, and premium valuation all matter. But for a medium-term investor willing to accept some volatility in exchange for a high-quality growth asset, PODD still looks compelling below the fair value estimate of $255. This is the kind of company that can compound for years. The trick, as usual, is refusing to pay any price just because the business deserves respect.